Typhoid fever: a review


  • Uttam Kumar Paul Department of Medicine, Mata Gujari Memorial Medical College, Kishanganj, Bihar, India
  • Arup Bandyopadhyay Department of Physiology, Mata Gujari Memorial Medical College, Kishanganj, Bihar, India




Typhoid fever, Review


Typhoid fever is still a deadly disease in developing countries, particularly in India. Although, the paediatric population is mostly affected by this disease, yet the disease is an important cause of morbidity and mortality in adult populations also. In India, most of the cases of typhoid fever are diagnosed clinically, or at the most by the Widal test which is not fool proof. The disease typhoid fever is an orally transmitted communicable infectious disease caused by the bacteria Salmonella typhi. It is usually caused by consuming impure water and contaminated food. Salmonella typhi is serologically positive for lipopolysaccharide antigens O9 and O12, protein flagellar antigen Hd, and polysaccharide capsular antigen Vi. S. typhi Vi-positive strains are more infectious and virulent than Vi-negative strains. Following the incubation period of 7 to 14 days, there is onset of fever and malaise. The fever is then accompanied by chills, headache, malaise, anorexia, nausea, vague abdominal discomfort, dry cough and myalgia. These are followed by coated tongue, tender abdomen, hepatomegaly, and splenomegaly. Azithromycin (10mg/kg) given once daily for seven days has proven effective in the treatment of typhoid fever in some adults and children. A dose of 1g per day for five days was also found to be more effective in most adults. Of the third generation cephalosporins, oral Cefixime (15-20mg per kg per day, for adults, 100-200mg twice daily) has been widely used. Intravenous third generation cephalosporins (ceftriaxone, cefotaxime) are effective. Aztreonam and imipenem are potential third line drugs.

Author Biography

Uttam Kumar Paul, Department of Medicine, Mata Gujari Memorial Medical College, Kishanganj, Bihar, India

Department of Medicine 



Osler W. The principles and practice of medicine: designed for the use of practitioners and students of medicine. 8th Ed. New York: D. Appleton; 1912:1-46.

Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004:82:346-53.

Stuart BM, Pullen RL. Typhoid; clinical analysis of 360 cases. Arch Intern Med (Chic). 1946;78:629-61.

Edelman R, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis. 1986;8:329-49

Committee on issues and priorities for new vaccine development, division of health promotion and disease prevention, division of international health. new vaccine development: establishing priorities: diseases of importance in developing countries. Washington (DC): National Academy Press; 1986:432.

Kothari A, Pruthi A, Chugh TD. The burden of enteric fever. J Infect Dev Countries. 2008;2:253-9.

Global burden of disease study [Internet]. Seattle (WA): Institute for Health Metrics and Evaluation; c2012. Available at: http://www.globalburden.org/. (Accessed: 3 March 2012).

Hoffman SL, Edman DC, Punjabi NH, Lesmana M, Cholid A, Sundah S, et al. Bone marrow aspirate culture superior to streptokinase clot culture and 8ml (1:10) blood-to-broth ratio blood culture for diagnosis of typhoid fever. Am J Trop Med Hyg. 1986;35:836-9.

Gilman RH, Terminel M, Levine MM, Hernandez-Mendoza P, Hornick RB. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet. 1975;1:1211-3.

Murray CJL, Lopez AD. Global burden of disease and injury series, 1st ed. Boston (MA). Harvard University Press; 1996:1.

Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. 1990;8:81-4.

Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987;1:1049-52.

Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 1990;336:891-4.

Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schulz D, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. 1987;2:1165-9.

Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis. 1982;145:292-5.

Crump JA, Youssef FG, Luby SP, Wasfy MO, Rangel JM, Taalat M, et al. Estimating the incidence of typhoid fever and other febrile illnesses in developing countries. Emerg Infect Dis. 2003;9:539-44.

Srikantiah P, Girgis FY, Luby SP, Jennings G, Wasfy MO, Crump JA, et al. Population-based surveillance of typhoid fever in Egypt. Am J Trop Med Hyg. 2006;74:114-9.

Brooks WA, Hossain A, Goswami D, Nahar K, Alam K, Ahmed N, et al. Bactaeremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis. 2005;11:326-9.

Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, et al. Typhoid fever in children aged less than 5 years. Lancet. 1999;354:734-7.

Chen X, Stanton B, Pach A, Nyamete A, Ochiai RL, Kaljee L, et al. Adults' perceived prevalence of enteric fever predicts laboratory-validated incidence of typhoid fever in children. J Health Popul Nutr. 2007;25:469-78.

Khan MI, Sahito SM, Khan MJ, Wassan SM, Shaikh AW, Maheshwari AK, et al. Enhanced disease surveillance through private health care sector cooperation in Karachi, Pakistan: experience from a vaccine trial. Bull World Health Organ. 2006;84:72-7.

Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2008;86:260-8.

Ochiai RL, Wang X, von Seidlein L, Yang J, Bhutta ZA, Bhattacharya SK, et al. Salmonella para typhi A rates, Asia. Emerg Infect Dis. 2005;11:1764-6.

Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med. 1987;317:1101-4.

Sur D, Ali M, von Seidlein L, Manna B, Deen JL, Acosta CJ, et al. Comparisons of predictors for typhoid and paratyphoid fever in Kolkata, India. BMC Pub Health. 2007;7:289.

Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med. 2009;361:335-44.

Siddiqui FJ, Rabbani F, Hasan R, Nizami SQ, Bhutta ZA. Typhoid fever in children: some epidemiological considerations from Karachi, Pakistan. Int J Infect Dis. 2006;10:215-22.

Yang HH, Wu CG, Xie GZ, Gu QW, Wang BR, Wang LY, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ. 2001;79:625-31.

Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacies of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med. 2001;344:1263-9.

Lin FY, Vo AH, Phan VB, Nguyen TT, Bryla D, Tran CT, et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg. 2000;62:644-8.

Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto, Totosudirjo H, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet. 1991;338:1055-9.

Vollaard AM, Ali S, Widjaja S, Asten HA, Visser LG, Surjadi C, et al. Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia. Trans R Soc Trop Med Hyg. 2005;99:440-50.

Dunn J, Pryor J, Saketa S, Wasale D, Buadromo E, Kishore K, et al. Laboratory-based Salmonella surveillance in Fiji, 2004-2005. Pac Health Dialog. 2005;12:53-9.

Lutui T. Ofanoa M, Finau S, Maika KV. Typhoid fever in Tonga. Pac Health Dialog. 1999;6:240-4.

The OzFoodNet Working Group. Monitoring the incidence and causes of diseases potentially transmitted by food in Australia: Annual report of the OzFoodNet Network, 2009. Commun Dis Intell. 2010;34:396-426.

Institute of Environmental Science and Research Limited, Population and Environmental Health Group. Notifiable and other diseases in New Zealand: 2009 annual surveillance report. Porirua (NZ): Institute of Environmental Science and Research Limited; 2010:63.

Centres for Disease Control and Prevention. Summary of notifiable diseases- United States, 2008 for Morbidity and Mortality Weekly Report. Atlanta (GA): Centres for Disease Control and Prevention; 2010:94.

Infectious Disease Surveillance Centre. Infectious Agents Surveillance Report: Typhoid fever and paratyphoid fever in Japan [Internet]. 2009 [cited 2011 April 15]; Available at: http://idsc.nih.go.jp/iasr/index.html.

European Centre for Disease Prevention and Control (ECDC). The European Surveillance System (TESSy). Stockholm (SE): ECDC; 2011.

Breiman RF, Cosmas L, Njuguna H, Audi A, Olack B, Ochieng JB, et al. Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: Implications for typhoid vaccine use in Africa. 2012;7:e29119.

Ram PK, Naheed A, Brooks WA et al. Risk factors for typhoid fever in a slum in Dhaka, Bangladesh. Epidemiol Infect. 2007;135:458-65.

Hosoglu S, Celen M, Geyik MF. Risk factors for typhoid fever among adult patients in Diyarbakir, Turkey. Epidemiol Infect. 2006;134:612-6.

Srikantiah P, Vafokulov S, Luby SP. Epidemiology and risk factors for endemic typhoid fever in Uzbekistan. Trop Med Int Health. 2007;12(7):838-47.

Vollaard AM, Ali S, Van Asten HAGH. Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia. JAMA. 2004;291:2607-15.

Dore K, Baxton J, Henry B. Risk factors for Salmonella typhimurium DT 104 and non-DT 104 infection: a Canadian multi-provincial case-control study. Epidemiol Infect. 2004;132:485-93.

Glynn MK, Reddy V, Hutwagner L. Prior antimicrobial agent use increases the risk of sporadic infections with multidrug-resistant Salmonella enterica serotype typhimurium: a Food Net case-control study. Clin Infect Dis. 2008;38(3):S227-36.

Pavia AT, Shipman LD, Wells JG. Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial sensitive Salmonella. J Infect Dis. 1990;161:255-60.

Barza M, Travers K. Excess infections due to antimicrobial resistance: the “Attributable Fraction”. Clin Infect Dis. 2002;34(3):S126-30.

Bhan MK, Bahl R, Sazawal S. Association between Helicobacter pylori infection and increased risk of typhoid fever. J Infect Dis. 2002;186:1857-60.

Dunstan SJ, Stephens HA, Blackwell JM. Genes of the class II and class III major histocompatibility complex are associated with typhoid fever in Vietnam. J Infect Dis. 2001;183:261-8.

Dharmana E, Joosten I, Tijssen HJ et al. HLADRB1*12 is associated with protection against complicated typhoid fever, independent of tumour necrosis factor alpha. Eur J Immunogenet. 2002;29:297-300.

Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. Clin Infect Dis. 2010;50(2):241-6.

Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med. 2002;347(22):1770-82.

Background Document: The diagnosis, treatment and prevention of typhoid fever. department of vaccines and biologicals, Geneva: World Health Organizations, 2003:1.

Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ. Typhoid fever: pathogenesis and immunologic control. N Engl J Med. 1970;283(13):686-691 and 283(14)739-46.

HouseD, Bishop A, Parry C, Dougan G, Wain J. Typhoid fever: pathogenesis and disease. Curr Opin Infect Dis. 2001;14(5):573-8.

Everest P, Wain J, Roberts M, Rook G, Dougan G. The molecular mechanisms of severe typhoid fever. Trends Microbiol. 2001;9(7):316-20.

Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever. BMJ. 2006;333(7558):78-82.

Ahasan HA, Rafiqueddin AKM, Chowdhury MAJ, Azad KAK, Karim ME, Hussain A. An unusual presentation of typhoid fever: report of four cases. Bangladesh J Med. 1993;11(3):101-3.

Hermans PW, Saha SK, van Leeuwen WJ, Verbrugh HA, van Belkum A, Goessens WH. Molecular typing of Salmonella typhi strains from Dhaka (Bangladesh) and development of DNA probes identifying plasmid-encoded multidrug-resistant isolates. J Clin Microbiol. 1996;34(6):1373-9.

Pegues DA, Miller SI. Salmonellosis. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine, 17th edn. New York: McGraw-Hill; 2008:956-9.

Ahasan HAMN, Islam QT, Choudhury MA, Azhar MA, Rafiquddin AKM, Hussain A, Kabir F. Hepatic manifestation of typhoid fever-report of four cases. Bangladesh J Med. 1993;4:19-21.

Stoll BJ, Glass RI, Banu H, Alam M. Enteric fever in patients admitted to a diarrhoeal disease hospital in Bangladesh. Trans R Soc Trop Med Hyg. 1983;77(4):548-51.

Fadeel MA, House BL, Wasfy MM, Klena JD, Habashy EE, Said MM, et al. Evaluation of a newly developed ELISA against Widal, TUBEX-TF and Typhidot for typhoid fever surveillance. J Infect Dev Countries. 2011;5(3):169-75.






Review Articles